摘要
应用Meta分析法对有关非那雄胺与前列腺癌发病率及病理分级关系的研究进行综合评价。符合标准的8篇文献进行Meta分析，计算比值比（OR）、95％可信区间（95％C1）。结果8篇文献，无异质性（Q=6．26，P=0．51），非那雄胺治疗组降低前列腺癌发病风险高于对照组，合并OR值为0．68（95％CI：0．65～O．71，Z=17．16，P=0．00）。Egger检验提示无发表偏倚（P=0．21）。对前列腺癌病理分级进行分组，非那雄胺治疗组前高于对照组，合并OR值为2．16（95％CI：1．97～2．36，Z=16．93，P=0．00）。非那雄胺治疗前列腺增生能降低前列腺癌的发病风险，也能使发生的前列腺癌的病理级别增高。
Analyzing all the related studies to evaluate the relationship between finasteride and incidence and pathology grad ing of prostate cancer by means of Meta--analysis. To analyze the references consistent with inclusion criteria , calculating the odds ratio and 95~/00 confidence interval. Eight publications were identified and found no heterogeneity（ Q--6.26, P= 0.51}. The risk of prostate cancer in BPH patients could be decreased in finasteride treatment than control group. The pooled OR for the study was 0.68（95%CI：0.65-0.71 ,Z=17.16,P=0.00）. Publication bias were not found in the study, by using Egger＇s test method （ P= 0.21）. In dividing the pathology grading of prostate cancer, the malignant degree of prostate cancer could be increased in BPH patients of using finasteride than case control. The summary OR for the study was 2.16{95GCI：1.97-2.36,Z=16.93,P=0.00）. Conclusion The risk of prostate cancer in BPH patients could be decrease in finasteride treatment, also could be increased in BPH patients of using finasteride.
出处
《医学与哲学（B）》
2011年第3期29-30,33,共3页
Medicine & Philosophy(B)
关键词
非那雄胺
前列腺癌
发病率
病理分级
META分析
finasteride, prostate cancer, incidence, pathology grading, Meta-- analysis
